Mink Current Deferred Revenue vs Cost Of Revenue Analysis

INKT Stock  USD 10.65  0.55  5.45%   
Mink Therapeutics financial indicator trend analysis is infinitely more than just investigating Mink Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mink Therapeutics is a good investment. Please check the relationship between Mink Therapeutics Current Deferred Revenue and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.

Current Deferred Revenue vs Cost Of Revenue

JavaScript chart by amCharts 3.21.1520162018202020222024155K160K165K170K175K180K185K 100K1M10M100M1B10B100B
JavaScript chart by amCharts 3.21.15Current Deferred Revenuetotal: 2.2MCost Of Revenuetotal: 59.3B

Current Deferred Revenue vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mink Therapeutics Current Deferred Revenue account and Cost Of Revenue. At this time, the significance of the direction appears to have almost no relationship.
Current Deferred RevenueCost Of RevenueDiversified AwayCurrent Deferred RevenueCost Of RevenueDiversified Away100%
The correlation between Mink Therapeutics' Current Deferred Revenue and Cost Of Revenue is 0.13. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Mink Therapeutics, assuming nothing else is changed. The correlation between historical values of Mink Therapeutics' Current Deferred Revenue and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Mink Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Current Deferred Revenue i.e., Mink Therapeutics' Current Deferred Revenue and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.13
Relationship DirectionPositive 
Relationship StrengthInsignificant

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cost Of Revenue

Cost of Revenue is found on Mink Therapeutics income statement and represents the costs associated with goods and services Mink Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most indicators from Mink Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mink Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.Selling General Administrative is likely to drop to about 5.5 M in 2025. Sales General And Administrative To Revenue is likely to drop to 0 in 2025
 2022 2024 2025 (projected)
Interest Expense253.3K228.0K216.6K
Depreciation And Amortization121.7K235.3K118.7K

Mink Therapeutics fundamental ratios Correlations

0.560.70.730.91-0.580.760.40.03-0.85-0.410.421.00.40.561.0-0.580.05-0.7-0.140.470.62-0.60.890.351.0
0.560.930.920.56-0.970.70.86-0.39-0.69-0.860.80.540.861.00.54-0.970.65-0.660.160.530.88-0.510.160.870.54
0.70.930.990.62-0.960.710.66-0.38-0.71-0.750.630.690.660.930.69-0.960.48-0.610.250.640.77-0.440.380.670.69
0.730.920.990.65-0.950.720.67-0.43-0.73-0.750.660.710.670.920.71-0.950.5-0.630.220.640.77-0.460.410.660.71
0.910.560.620.65-0.580.930.58-0.14-0.98-0.60.530.910.580.560.91-0.580.25-0.92-0.490.130.79-0.870.710.550.9
-0.58-0.97-0.96-0.95-0.58-0.72-0.820.470.710.89-0.81-0.57-0.82-0.97-0.571.0-0.590.66-0.17-0.56-0.850.5-0.18-0.82-0.56
0.760.70.710.720.93-0.720.76-0.41-0.98-0.820.650.760.760.70.76-0.720.54-0.98-0.50.030.92-0.940.440.750.74
0.40.860.660.670.58-0.820.76-0.45-0.73-0.940.940.381.00.860.38-0.820.72-0.8-0.240.150.94-0.72-0.050.990.37
0.03-0.39-0.38-0.43-0.140.47-0.41-0.450.30.6-0.410.03-0.45-0.390.030.46-0.80.360.180.17-0.410.370.29-0.450.05
-0.85-0.69-0.71-0.73-0.980.71-0.98-0.730.30.76-0.67-0.85-0.73-0.69-0.850.71-0.420.970.46-0.14-0.890.91-0.57-0.7-0.84
-0.41-0.86-0.75-0.75-0.60.89-0.82-0.940.60.76-0.86-0.4-0.94-0.86-0.40.89-0.720.810.22-0.14-0.930.730.04-0.94-0.39
0.420.80.630.660.53-0.810.650.94-0.41-0.67-0.860.40.940.80.4-0.80.58-0.68-0.120.320.83-0.590.00.890.4
1.00.540.690.710.91-0.570.760.380.03-0.85-0.40.40.380.541.0-0.570.04-0.7-0.150.450.61-0.60.90.341.0
0.40.860.660.670.58-0.820.761.0-0.45-0.73-0.940.940.380.860.38-0.820.72-0.8-0.240.150.94-0.72-0.050.990.37
0.561.00.930.920.56-0.970.70.86-0.39-0.69-0.860.80.540.860.54-0.970.65-0.660.160.530.88-0.510.160.870.54
1.00.540.690.710.91-0.570.760.380.03-0.85-0.40.41.00.380.54-0.570.04-0.7-0.150.450.61-0.60.90.341.0
-0.58-0.97-0.96-0.95-0.581.0-0.72-0.820.460.710.89-0.8-0.57-0.82-0.97-0.57-0.580.65-0.18-0.56-0.850.49-0.18-0.82-0.56
0.050.650.480.50.25-0.590.540.72-0.8-0.42-0.720.580.040.720.650.04-0.58-0.54-0.22-0.150.68-0.54-0.290.760.03
-0.7-0.66-0.61-0.63-0.920.66-0.98-0.80.360.970.81-0.68-0.7-0.8-0.66-0.70.65-0.540.60.06-0.930.98-0.39-0.78-0.69
-0.140.160.250.22-0.49-0.17-0.5-0.240.180.460.22-0.12-0.15-0.240.16-0.15-0.18-0.220.60.78-0.330.75-0.09-0.23-0.13
0.470.530.640.640.13-0.560.030.150.17-0.14-0.140.320.450.150.530.45-0.56-0.150.060.780.150.270.390.110.47
0.620.880.770.770.79-0.850.920.94-0.41-0.89-0.930.830.610.940.880.61-0.850.68-0.93-0.330.15-0.850.210.940.6
-0.6-0.51-0.44-0.46-0.870.5-0.94-0.720.370.910.73-0.59-0.6-0.72-0.51-0.60.49-0.540.980.750.27-0.85-0.32-0.71-0.58
0.890.160.380.410.71-0.180.44-0.050.29-0.570.040.00.9-0.050.160.9-0.18-0.29-0.39-0.090.390.21-0.32-0.10.9
0.350.870.670.660.55-0.820.750.99-0.45-0.7-0.940.890.340.990.870.34-0.820.76-0.78-0.230.110.94-0.71-0.10.32
1.00.540.690.710.9-0.560.740.370.05-0.84-0.390.41.00.370.541.0-0.560.03-0.69-0.130.470.6-0.580.90.32
Click cells to compare fundamentals

Mink Therapeutics Account Relationship Matchups

Mink Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets4.6M40.2M21.5M4.6M5.2M5.0M
Other Current Liab10.8M13.5M6.9M7.5M8.6M8.5M
Total Current Liabilities14.2M16.5M12.7M11.4M13.1M13.7M
Total Stockholder Equity(53.9M)23.8M(401.3K)(18.1M)(20.8M)(21.8M)
Property Plant And Equipment Net458.4K606.6K1.1M954.0K1.1M764.8K
Net Debt41.1M(38.9M)(19.6M)(3.4M)(3.0M)(2.9M)
Retained Earnings(52.7M)(82.9M)(110.9M)(133.4M)(120.1M)(126.1M)
Accounts Payable3.1M3.0M5.8M3.9M4.5M4.0M
Cash2.7M38.9M19.6M3.4M3.9M3.7M
Non Current Assets Total458.4K606.6K1.1M954.0K1.1M764.8K
Cash And Short Term Investments2.7M38.9M19.6M3.4M3.9M3.7M
Liabilities And Stockholders Equity4.6M40.2M21.5M4.6M5.2M5.0M
Non Current Liabilities Total44.2M3.0M9.2M11.2M10.1M15.7M
Other Current Assets1.4M723.1K769.0K231.1K208.0K197.6K
Other Stockholder Equity383.7K107.3M110.8M115.8M133.1M73.6M
Total Liab58.4M16.5M21.9M22.6M20.3M25.1M
Net Invested Capital(10.1M)23.8M(401.3K)(18.1M)(16.2M)(15.4M)
Property Plant And Equipment Gross556.5K775.2K1.4M1.4M1.7M1.0M
Total Current Assets4.1M39.6M20.4M3.6M4.1M3.9M
Accumulated Other Comprehensive Income(1.5M)(625.3K)(292.5K)(430.9K)(495.6K)(520.4K)
Capital Stock242.0335.0339.0346.0397.9330.66
Net Working Capital(10.1M)23.2M7.7M(7.8M)(9.0M)(8.5M)
Common Stock242.0335.0339.0346.0397.9330.66

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…